Open Access. Powered by Scholars. Published by Universities.®
Biochemistry, Biophysics, and Structural Biology Commons™
Open Access. Powered by Scholars. Published by Universities.®
- File Type
Articles 1 - 3 of 3
Full-Text Articles in Biochemistry, Biophysics, and Structural Biology
Molecular Basis For Drug Resistance In Hiv-1 Protease, Akbar Ali, Rajintha M. Bandaranayake, Yufeng Cai, Nancy M. King, Madhavi Kolli, Seema Mittal, Jennifer E. Foulkes-Murzycki, Madhavi N. L. Nalam, Ellen A. Nalivaika, Aysegul Ozen, Moses Prabu-Jeyabalan, Kelly Thayer, Celia A. Schiffer
Molecular Basis For Drug Resistance In Hiv-1 Protease, Akbar Ali, Rajintha M. Bandaranayake, Yufeng Cai, Nancy M. King, Madhavi Kolli, Seema Mittal, Jennifer E. Foulkes-Murzycki, Madhavi N. L. Nalam, Ellen A. Nalivaika, Aysegul Ozen, Moses Prabu-Jeyabalan, Kelly Thayer, Celia A. Schiffer
Celia A. Schiffer
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the inhibitors bind are well characterized. From this structural understanding the molecular basis for drug resistance in HIV-1 protease can be elucidated. Selected mutations in response to therapy and diversity between clades in HIV-1 protease have altered the shape of the active site, potentially altered the dynamics and even altered the sequence of the cleavage sites in the Gag polyprotein. All …
Tmc310911, A Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, Shows In Vitro An Improved Resistance Profile And Higher Genetic Barrier To Resistance Compared With Current Protease Inhibitors, Inge Dierynck, Herwig Van Marck, Marcia Van Ginderen, Tim Jonckers, Madhavi Nalam, Celia Schiffer, Araz Raoof, Guenter Kraus, Gaston Picchio
Tmc310911, A Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, Shows In Vitro An Improved Resistance Profile And Higher Genetic Barrier To Resistance Compared With Current Protease Inhibitors, Inge Dierynck, Herwig Van Marck, Marcia Van Ginderen, Tim Jonckers, Madhavi Nalam, Celia Schiffer, Araz Raoof, Guenter Kraus, Gaston Picchio
Celia A. Schiffer
TMC310911 is a novel human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) structurally closely related to darunavir (DRV) but with improved virological characteristics. TMC310911 has potent activity against wild-type (WT) HIV-1 (median 50% effective concentration [EC(50)], 14 nM) and a wide spectrum of recombinant HIV-1 clinical isolates, including multiple-PI-resistant strains with decreased susceptibility to currently approved PIs (fold change [FC] in EC(50), >10). For a panel of 2,011 recombinant clinical isolates with decreased susceptibility to at least one of the currently approved PIs, the FC in TMC310911 EC(50) was
Three Residues In Hiv-1 Matrix Contribute To Protease Inhibitor Susceptibility And Replication Capacity, Chris Parry, Madhavi Kolli, Richard Myers, Patricia Cane, Celia Schiffer, Deenan Pillay
Three Residues In Hiv-1 Matrix Contribute To Protease Inhibitor Susceptibility And Replication Capacity, Chris Parry, Madhavi Kolli, Richard Myers, Patricia Cane, Celia Schiffer, Deenan Pillay
Celia A. Schiffer
Other than cleavage site mutations, there is little data on specific positions within Gag that impact on HIV protease inhibitor susceptibility. We have recently shown that non-cleavage site mutations in gag, particularly within matrix protein can restore replication capacity and further reduce protease inhibitor drug susceptibility when coexpressed with a drug-resistant (mutant) protease. The matrix protein of this patient-derived virus was studied in order to identify specific changes responsible for this phenotype. Three amino acid changes in matrix (R76K, Y79F, and T81A) had an impact on replication capacity as well as drug susceptibility. Introduction of these three changes into wild-type …